News headlines about Oxford Immunotec Global PLC (NASDAQ:OXFD) have trended somewhat positive on Sunday, Accern reports. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Oxford Immunotec Global PLC earned a news impact score of 0.02 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 44.7294906129706 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the headlines that may have effected Accern’s scoring:
- Zacks: Analysts Expect Oxford Immunotec Global PLC (OXFD) Will Announce Earnings of -$0.34 Per Share (americanbankingnews.com)
- Oxford Immunotec Global PLC (OXFD) Given Average Recommendation of “Hold” by Brokerages (americanbankingnews.com)
- Oxford Immunotec to Present at the Jefferies 2017 London Healthcare Conference (finance.yahoo.com)
- ETFs with exposure to Oxford Immunotec Global Plc : November 6, 2017 (finance.yahoo.com)
A number of brokerages have recently issued reports on OXFD. Zacks Investment Research downgraded Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Saturday, November 4th. BTIG Research set a $21.00 target price on Oxford Immunotec Global PLC and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Robert W. Baird reissued a “buy” rating and set a $20.00 target price on shares of Oxford Immunotec Global PLC in a research note on Wednesday, November 1st. ValuEngine downgraded Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Tuesday, October 31st. Finally, Piper Jaffray Companies cut their target price on Oxford Immunotec Global PLC from $26.00 to $19.00 and set an “overweight” rating for the company in a research note on Tuesday, October 31st. Three analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. Oxford Immunotec Global PLC currently has an average rating of “Hold” and an average target price of $19.75.
Oxford Immunotec Global PLC (OXFD) traded up $0.06 on Friday, hitting $12.94. The company had a trading volume of 64,700 shares, compared to its average volume of 176,966. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.30 and a current ratio of 4.72. Oxford Immunotec Global PLC has a 1-year low of $12.19 and a 1-year high of $19.51.
In other Oxford Immunotec Global PLC news, CEO Peter Wrighton-Smith sold 55,000 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $16.78, for a total transaction of $922,900.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Peter Edwardson sold 9,739 shares of the stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $16.14, for a total value of $157,187.46. Following the sale, the chief operating officer now owns 92,905 shares in the company, valued at approximately $1,499,486.70. The disclosure for this sale can be found here. In the last quarter, insiders have sold 70,739 shares of company stock worth $1,167,597. 8.11% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: “Oxford Immunotec Global PLC (OXFD) Earning Somewhat Favorable News Coverage, Report Finds” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2017/11/12/oxford-immunotec-global-plc-oxfd-earning-somewhat-favorable-news-coverage-report-finds.html.
About Oxford Immunotec Global PLC
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.